Unknown

Dataset Information

0

Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease.


ABSTRACT: BACKGROUND:Plasminogen activator inhibitor type 1 (PAI-1) plays an essential role in the fibrinolysis system and thrombosis. Population studies have reported that blood PAI-1 levels are associated with increased risk of coronary heart disease (CHD). However, it is unclear whether the association reflects a causal influence of PAI-1 on CHD risk. METHODS AND RESULTS:To evaluate the association between PAI-1 and CHD, we applied a 3-step strategy. First, we investigated the observational association between PAI-1 and CHD incidence using a systematic review based on a literature search for PAI-1 and CHD studies. Second, we explored the causal association between PAI-1 and CHD using a Mendelian randomization approach using summary statistics from large genome-wide association studies. Finally, we explored the causal effect of PAI-1 on cardiovascular risk factors including metabolic and subclinical atherosclerosis measures. In the systematic meta-analysis, the highest quantile of blood PAI-1 level was associated with higher CHD risk comparing with the lowest quantile (odds ratio=2.17; 95% CI: 1.53, 3.07) in an age- and sex-adjusted model. The effect size was reduced in studies using a multivariable-adjusted model (odds ratio=1.46; 95% CI: 1.13, 1.88). The Mendelian randomization analyses suggested a causal effect of increased PAI-1 level on CHD risk (odds ratio=1.22 per unit increase of log-transformed PAI-1; 95% CI: 1.01, 1.47). In addition, we also detected a causal effect of PAI-1 on elevating blood glucose and high-density lipoprotein cholesterol. CONCLUSIONS:Our study indicates a causal effect of elevated PAI-1 level on CHD risk, which may be mediated by glucose dysfunction.

SUBMITTER: Song C 

PROVIDER: S-EPMC5669150 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease.

Song Ci C   Burgess Stephen S   Eicher John D JD   O'Donnell Christopher J CJ   Johnson Andrew D AD  

Journal of the American Heart Association 20170526 6


<h4>Background</h4>Plasminogen activator inhibitor type 1 (PAI-1) plays an essential role in the fibrinolysis system and thrombosis. Population studies have reported that blood PAI-1 levels are associated with increased risk of coronary heart disease (CHD). However, it is unclear whether the association reflects a causal influence of PAI-1 on CHD risk.<h4>Methods and results</h4>To evaluate the association between PAI-1 and CHD, we applied a 3-step strategy. First, we investigated the observatio  ...[more]

Similar Datasets

| S-EPMC3336151 | biostudies-literature
| S-EPMC3044959 | biostudies-literature
| S-EPMC5428408 | biostudies-literature
| S-EPMC4942808 | biostudies-literature
| S-EPMC7711432 | biostudies-literature
| S-EPMC4238518 | biostudies-literature
| S-EPMC4731420 | biostudies-literature
| S-EPMC3418576 | biostudies-literature
| S-EPMC1135393 | biostudies-other
| S-EPMC4646234 | biostudies-literature